Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$4.2 million.

  • Protalix BioTherapeutics' Net Cash Flow fell 11733.79% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year decrease of 15022.38%. This contributed to the annual value of -$3.9 million for FY2024, which is 15874.64% down from last year.
  • Protalix BioTherapeutics' Net Cash Flow amounted to -$4.2 million in Q3 2025, which was down 11733.79% from -$1.6 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Net Cash Flow peaked at $28.3 million during Q4 2021, and registered a low of -$27.8 million during Q3 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$294000.0 (2025), whereas its average is $701842.1.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Net Cash Flow soared by 50296.12% in 2021, and later crashed by 148383.46% in 2022.
  • Over the past 5 years, Protalix BioTherapeutics' Net Cash Flow (Quarter) stood at $28.3 million in 2021, then crashed by 77.33% to $6.4 million in 2022, then crashed by 49.31% to $3.3 million in 2023, then plummeted by 336.8% to -$7.7 million in 2024, then surged by 45.01% to -$4.2 million in 2025.
  • Its Net Cash Flow stands at -$4.2 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$294000.0 for Q1 2025.